| Literature DB >> 27989805 |
James Kirby1, Kevin L Dietzel2, Gale Wichmann2, Rossana Chan1, Eugene Antipov2, Nathan Moss2, Edward E K Baidoo3, Peter Jackson2, Sara P Gaucher2, Shayin Gottlieb2, Jeremy LaBarge2, Tina Mahatdejkul2, Kristy M Hawkins2, Sheela Muley2, Jack D Newman2, Pinghua Liu4, Jay D Keasling5, Lishan Zhao6.
Abstract
Isoprenoids are used in many commercial applications and much work has gone into engineering microbial hosts for their production. Isoprenoids are produced either from acetyl-CoA via the mevalonate pathway or from pyruvate and glyceraldehyde 3-phosphate via the 1-deoxy-D-xylulose 5-phosphate (DXP) pathway. Saccharomyces cerevisiae exclusively utilizes the mevalonate pathway to synthesize native isoprenoids and in fact the alternative DXP pathway has never been found or successfully reconstructed in the eukaryotic cytosol. There are, however, several advantages to isoprenoid synthesis via the DXP pathway, such as a higher theoretical yield, and it has long been a goal to transplant the pathway into yeast. In this work, we investigate and address barriers to DXP pathway functionality in S. cerevisiae using a combination of synthetic biology, biochemistry and metabolomics. We report, for the first time, functional expression of the DXP pathway in S. cerevisiae. Under low aeration conditions, an engineered strain relying solely on the DXP pathway for isoprenoid biosynthesis achieved an endpoint biomass 80% of that of the same strain using the mevalonate pathway.Entities:
Keywords: MEP pathway; metabolic engineering; terpene; yeast
Mesh:
Substances:
Year: 2016 PMID: 27989805 PMCID: PMC5718835 DOI: 10.1016/j.ymben.2016.10.017
Source DB: PubMed Journal: Metab Eng ISSN: 1096-7176 Impact factor: 9.783